Evidence map›Paper›PMID 31560172›Full record

ArticleAnnals of clinical and translational neurology2019

Slow-channel myasthenia due to novel mutation in M2 domain of AChR delta subunit.

Xin-Ming Shen, Margherita Milone, Hang-Long Wang, Brenda Banwell, Duygu Selcen, Steven M Sine, Andrew G Engel

Abstract readCase Reports
In one paragraph

Article in Annals of clinical and translational neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Slow-Channel Congenital Myasthenic Syndrome Due toJournal of clinical neurology (Seoul, Korea) · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xin-Ming ShenDepartment of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7087-5166
Margherita MiloneDepartment of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, Minnesota.
Hang-Long WangDepartment of Neurology and Vesicular Biology Laboratory, Mayo Clinic, Rochester, Minnesota.
Brenda BanwellDivision of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Duygu SelcenDepartment of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, Minnesota.
Steven M SineDepartment of Physiology and Biomedical Engineering and Receptor Biology Laboratory, Mayo Clinic, Rochester, Minnesota.
Andrew G EngelDepartment of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, Minnesota.

Funding

STRUCTURE/FUNCTION OF THE ACETYLCHOLINE RECEPTORR01NS031744 · NINDS · MAYO CLINIC ROCHESTER · PI SINE, STEVEN M · 1992 to 2023
$7.3M
Structure and Function of the Acetylcholine ReceptorR37NS031744 · NINDS · MAYO CLINIC ROCHESTER · PI SINE, STEVEN M · 2001 to 2007
$4.1M
Congenital Myasthenic SyndromesR01NS109491 · NINDS · MAYO CLINIC ROCHESTER · PI ENGEL, ANDREW GEORGE, SELCEN, DUYGU · 2019 to 2022
$1.8M
Myasthenia Gravis Foundation FP00094864NINDS NIH HHS R01 NS031744NINDS NIH HHS R01 NS109491NINDS NIH HHS R37 NS031744
6 · The paper itself

Abstract

objectiveTo characterize the molecular and phenotypic basis of a severe slow-channel congenital myasthenic syndrome (SCCMS).

methodsIntracellular and single-channel recordings from patient endplates; alpha-bungarotoxin binding studies; direct sequencing of AChR genes; microsatellite analysis; kinetic analysis of AChR activation; homology modeling of adult human AChR structure.

resultsAmong 24 variants reported to cause SCCMS only two appear in the AChR δ-subunit. We here report a 16-year-old patient harboring a novel δL273F mutation (δL294F in HGVS nomenclature) in the second transmembrane domain (M2) of the AChR δ subunit. Kinetic analyses with ACh and the weak agonist choline indicate that δL273F prolongs the channel opening bursts 9.4-fold due to a 75-fold increase in channel gating efficiency, whereas a previously identified εL269F mutation (εL289F in HGVS nomenclature) at an equivalent location in the AChR ε-subunit prolongs channel opening bursts 4.4-fold due to a 30-fold increase in gating efficiency. Structural modeling of AChR predicts that inter-helical hydrophobic interactions between the mutant residue in the δ and ε subunit and nearby M2 domain residues in neighboring α subunits contribute to structural stability of the open relative to the closed channel states.

interpretationThe greater increase in gating efficiency by δL273F than by εL269F explains why δL273F has more severe clinical effects. Both δL273F and εL269F impair channel gating by disrupting hydrophobic interactions with neighboring α-subunits. Differences in the extent of impairment of channel gating in δ and ε mutant receptors suggest unequal contributions of ε/α and δ/α subunit pairs to gating efficiency.

Indexed as

Motor EndplateMyasthenic Syndromes, CongenitalAdolescentFemaleHumansReceptors, CholinergicCHRND protein, humanReceptors, Cholinergic

Identifiers

PMID31560172
PMCPMC6801167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.